Prashant K. Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prashant K. Singh has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Bo Xu
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications - David W. Goodrich
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications - Eduardo Cortes Gomez
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
34 shared publications - Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
34 shared publications - Jianmin Wang
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA
34 shared publications - Jie Wang
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York
34 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Antibodies used in Flow Cytometry, Multi-spectral Flow Cytometry, and PhenoCycler Immunofluorescence.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Antibodies used in Flow Cytometry, Multi-spectral Flow Cytometry, and PhenoCycler Immunofluorescence.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
STK11 deletion results in increased neutrophilic and decreased T cell inflammation in the TME.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
STK11 deletion results in increased neutrophilic and decreased T cell inflammation in the TME.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
ScRNA-seq of CMT167-STK11KO versus CMT167-STK11WT tumor subsets and orthotopic implantation.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
ScRNA-seq of CMT167-STK11KO versus CMT167-STK11WT tumor subsets and orthotopic implantation.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Gene Expression Analysis of TCGA KRAS/STK11 mutant NSCLC RNAseq.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Gene Expression Analysis of TCGA KRAS/STK11 mutant NSCLC RNAseq.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
CMT167-STK11KO tumor growth in wildtype versus immunodeficient nude mice.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
CMT167-STK11KO tumor growth in wildtype versus immunodeficient nude mice.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
STK11 deletion in syngeneic Lacun3 LUAD mouse model results in increased C3 expression and resistance to anti–PD-1 therapy.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
STK11 deletion in syngeneic Lacun3 LUAD mouse model results in increased C3 expression and resistance to anti–PD-1 therapy.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Cytokine evaluation of CMT167-STK11KO and STK11WT tumors.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Cytokine evaluation of CMT167-STK11KO and STK11WT tumors.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Neutrophil depletion with anti-Ly6G treatment in mice enhanced the effect of anti–PD-1 therapy in CMT167-STK11KO tumors.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
Neutrophil depletion with anti-Ly6G treatment in mice enhanced the effect of anti–PD-1 therapy in CMT167-STK11KO tumors.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
CXCL2KO alters the phenotype of neutrophils in STK11KO TME.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
CXCL2KO alters the phenotype of neutrophils in STK11KO TME.